Most Recent
NSW Ports hit with second competition lawsuit over ports agreement
NSW Ports is facing a new lawsuit over an allegedly anti-competitive agreement entered into with the NSW state government for the privatisation of Port Botany and Port Kembla, which is the subject of a separate case brought by the competition regulator.
Bayer faces appeals of IP Australia rulings on antiseptic patent
Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.
Ex-CFO of Octaviar unit charged with $4.6M fraud
The former chief financial officer of a unit of collapsed Gold Coast finance company Octaviar Investments is facing fraud charges for allegedly misappropriating more than $4.6 million in company funds for his personal use.
Botox alternatives likened to ‘iPhone accessories’ as trade mark trial kicks off
In its opening submissions in a trade mark case brought by Botox maker Allergan, Australian cosmetics brand Self Care compared its used of the word Botox to describe its alternative cosmetic products to the iPhone secondary accessories market, saying its use did not imply an affiliation with the injectable wrinkle treatment's maker.
Piper Alderman partner rejected offer to leave on a ‘dignified basis’, court told
A senior Piper Alderman partner who has launched a sex discrimination case against the law firm rejected “reasonable settlement offers” that would have allowed her to leave the partnership on a “dignified basis”, counsel for the firm has told a court.
Key witness in Hastie Services execs’ trial pointed the finger to save herself, jury hears
A former finance manager from Hastie Services and key witness for the prosecution in the criminal trial against two of the company's former executives only pointed the finger at former COO Ian Thompson to avoid jail time herself, a jury has heard.
Novartis appeals IP Australia decision invalidating MS drug patent
Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step.
Judge denies costs to objector in Willmott Forest MIS class actions
An investor who successfully objected to an initial settlement of four class actions over the failed Willmott Forests managed investment scheme lost a bid to have his legal costs paid by the defendants, with a judge saying the objections were not the primary basis for his refusal to sign off on the agreement.
Westpac unit in talks to settle class action over Samra Ponzi scheme
Westpac unit BankSA is in talks to resolve a class action alleging it failed to detect the fraud of convicted Ponzi schemer Michael Samra.
ACCC says LG should pay $700,000 for misleading customers about repair rights
Electronics giant LG should pay a $700,000 fine for twice breaching the Australian Consumer Law when its offshore call centre workers misled customers complaining about faulty television sets that they had no rights to a repair, replacement or refund under the law, a court has been told.